Profile
Edward Stuart was the founder of U3 Pharma AG (founded in 2001) where he held the title of Chief Executive Officer and CT Atlantic Ltd.
(founded in 2008) where he held the title of Chief Executive Officer from 2008 to 2009.
Dr. Stuart is also the founder of HS LifeSciences GmbH, QureInvest AG.
He held the position of Chief Executive Officer at Neurimmune Therapeutics.
Dr. Stuart earned an MBA from Imperial College London in 1998, completed undergraduate and graduate degrees at University College Dublin, and earned a doctorate from the University of Bern in 1992.
Former positions of Edward Stuart
| Companies | Position | End |
|---|---|---|
| Neurimmune Therapeutics | President | 01/01/2008 |
QureInvest AG
 QureInvest AG Investment ManagersFinance QureInvest AG targets seed and early stage companies located in Germany and Switzerland. It seeks investments in biotechnology and life sciences firms. | Founder | - |
| HS LifeSciences GmbH | Founder | - |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Founder | - |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Chief Executive Officer | - |
Training of Edward Stuart
| Imperial College London | Masters Business Admin |
| University College Dublin | Graduate Degree |
| University of Bern | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
CT Atlantic Ltd.
CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
| Neurimmune Therapeutics | |
| HS LifeSciences GmbH | Finance |
QureInvest AG
QureInvest AG Investment ManagersFinance QureInvest AG targets seed and early stage companies located in Germany and Switzerland. It seeks investments in biotechnology and life sciences firms. | Finance |
- Stock Market
- Insiders
- Edward Stuart
